Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Rhea-AI Summary

Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), announced participation in three healthcare investment conferences. On May 2, CEO Kris Vaddi will engage in a fireside chat at the H. C. Wainwright BioConnect Investor Conference at Nasdaq. The Bank of America Securities 2023 Healthcare Conference will feature Dr. Jane Huang and CFO Laurent Chardonnet in one-on-one meetings on May 10 and 11, with Dr. Huang presenting a fireside chat on May 10 at 4:20 p.m. PT. Lastly, during the JMP Securities Life Sciences Conference on May 15 and 16, Dr. Vaddi and Mr. Chardonnet will hold one-on-one meetings, with Dr. Vaddi participating in a fireside chat on May 15 at noon ET. Prelude's pipeline includes four promising drug candidates targeting key cancer pathways.

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.

Details are as follows:

• H. C. Wainwright BioConnect Investor Conference at Nasdaq
  Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on Tuesday, May 2, at 1:30 p.m. ET. The live webcast is available here. The Company will also host one-on-one investor meetings during the day.
  

• Bank of America Securities 2023 Healthcare Conference
  Jane Huang, MD, President and Chief Medical Officer and Laurent Chardonnet, Chief Financial Officer, will conduct one-on-one meetings on Wednesday, May 10 and Thursday May 11. Dr. Huang will participate in a fireside chat on May 10 at 4:20 p.m. PT/7:20 p.m. ET. The live webcast will be available here, and will be available for replay until August 11, 2023.
  

• JMP Securities Life Sciences Conference
  Dr. Vaddi and Mr. Chardonnet will conduct one-on-one meetings on Monday, May 15 and Tuesday May 16 and Dr. Vaddi will participate in a fireside chat at 12 noon ET, on May 15. The live webcast is available here and will be available for replay for 90 days.

About Prelude Therapeutics 
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789, an IV administered, potent and highly selective SMARCA2 degrader.

For more information, visit our website and follow us on LinkedIn and Twitter.

Investor Contact: 
Lindsey Trickett 
Vice President, Investor Relations 
240.543.7970 
ltrickett@preludetx.com

Media Contact: 
Helen Shik  
Shik Communications  
617.510.4373
Helen@ShikCommunications.com

FAQ

What conferences is Prelude Therapeutics participating in May 2023?

Prelude Therapeutics is participating in the H. C. Wainwright BioConnect Investor Conference, the Bank of America Securities 2023 Healthcare Conference, and the JMP Securities Life Sciences Conference.

When will Kris Vaddi speak at the H. C. Wainwright BioConnect Investor Conference?

Kris Vaddi will speak on May 2, 2023, at 1:30 p.m. ET.

What is the schedule for the Bank of America Securities 2023 Healthcare Conference?

The conference includes one-on-one meetings on May 10 and 11, and Dr. Huang's fireside chat on May 10 at 4:20 p.m. PT.

How can I access the webcasts for Prelude Therapeutics' conference presentations?

Webcasts for the conferences can be accessed via the links provided in their press release.

What drug candidates are in Prelude Therapeutics' pipeline?

Prelude has four candidates: PRT1419, PRT2527, PRT3645, and PRT3789, targeting significant cancer pathways.